Global preventive vaccines market is estimated to be valued at USD 50.41 Bn in 2024 and is expected to exhibit a CAGR of 9.7% during the forecast period (2024-2031). The global preventive vaccines market is witnessing a period of growth owing to the rising burden of various infectious diseases across the world. Preventive vaccines are biological preparations that enhance immunity against certain diseases and help prevent future infections. Over the years, various advancements in vaccinology have enabled the development of immunization to safeguard individuals from life-threatening illnesses. Moreover, growing awareness regarding immunization and continuous innovation in vaccine technologies are fueling the demand for preventive vaccines. Governments of several countries have implemented national immunization programs to promote vaccination coverage. Rising healthcare expenditures on communicable diseases from public and private sources are also contributing to the expansion of the preventive vaccines market. However, high research and development costs involved in new vaccine development and lack of awareness in low-income nations are some of the factors hindering the market growth.

Market Dynamics:

The global preventive vaccines market growth is primarily driven by the increasing prevalence of target infectious diseases. Significant unmet medical needs associated with bacterial and viral infections across the emerging nations are driving the demand for immunization and vaccination programs. Various initiatives taken by governments and non-profit organizations to strengthen national immunization programs have augmented the uptake of preventive vaccines. For instance, the National Immunization Program of India aims to provide vaccines against 12 life-threatening diseases free of cost. Technological advancements in vaccine product development with improved immunogenicity and stability have unlocked new growth opportunities. However, high costs associated with new vaccine R&D, testing, clinical trials, and production are expected to restrain the market expansion to some extent during the forecast period. Rising focus on development of combination vaccines to lower vaccination costs offers lucrative opportunities in the forthcoming years.

Key Features of the Study:

• This report provides in-depth analysis of the global preventive vaccines market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global preventive vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Sanofi, Pfizer Inc., Merck & Co. Inc., GSK plc., Takeda Pharmaceutical Company Limited, AstraZeneca, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., Zydus Group, Moderna, Inc., Sinopharm Group Co. Ltd., Valneva SE, Serum Institute of India Pvt. Ltd., Johnson & Johnson Services, Inc., Bharat Biotech, and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global preventive vaccines market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preventive vaccines market.

Detailed Segmentation-

• By Vaccine Type:
  • Live/Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Others
• By Disease Type:
  • Pneumococcal
  • Poliovirus
  • Hepatitis
  • Influenza
  • Measles
  • Rubella 
  • Others
• By Distribution Channel:
  • Public
  • Private
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Sanofi
• Pfizer Inc.
• Merck & Co. Inc.
• GSK plc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Daiichi Sankyo Co. Ltd.
• Emergent BioSolutions Inc.
• Novavax Inc.
• Zydus Group
• Moderna, Inc.
• Sinopharm Group Co. Ltd.
• Valneva SE
• Serum Institute of India Pvt. Ltd.
• Johnson & Johnson Services, Inc.
• Bharat Biotech
• Regeneron Pharmaceuticals Inc.